VSTM - Conference and earnings call announcements

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to present at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston: November 9, 4:00-4:25pm ET Wolfe Research Healthcare Conference in New York City: November 10, 4:00-4:30pm ET Jefferies London Healthcare Conference in London: November 16, 2:30-2:55pm GMT A live webcast of the fireside chats can be accessed under "Events & Presentations" on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the

VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of patients ongoing >6 months and a 67% landmark 6-month PFS rate FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end Early results in heavily pretreated 3L+ colorectal cancer (CRC) include 33% unconfirmed ORR with 900 mg QD in combination anti-EGFR therapy with no patients with target lesion increases VS-7375 achieved 43% confirmed ORR with 600 mg QD monotherapy in 2L+ non-small cell lung cancer (NSCLC) including patients with prior taxane tr

SAN DIEGO, Sept. 28, 2026 /CNW/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question

Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical update reported in June 2026 and provide the first broader safety and efficacy assessment of VS-7375 across these tumor types. VS-7375 is a potent

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET A live webcast of the fireside chats can be accessed under "Events & Presentations" on the Company’s website at www.verastem.com. A replay of the webcasts will be

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. A

Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251 Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to develo

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in November: Guggenheim Healthcare Conference 2025: Fireside chat on Tuesday, November 11 at 1:00 pm ET Jefferies Global Healthcare Conference in London: Fireside chat on Wednesday, November 19 at 2:30 pm GMT (9:30 am ET) A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcasts will b

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8 at 12:00 pm ET A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcasts will

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Cue Biopharma, Inc. (NASDAQ:CUE)

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET 2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at 3:35 pm ET Alliance Global Partners/A.G.P.'s Annual Healthcare Company Showcase: Virtual fireside chat on Wednesday, May 21 at 10:20 am ET A live webcast of the fireside chats can be accessed under events on Verastem

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the company's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a late-stage development biopharmaceutical com

Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma cash position of $128.6 million including debt refinancing and equity issuance provides cash runway beyond FDA approval Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announced a strategic collaboration with IQVIA Inc. (IQVIA) to leverage IQVIA's world-class infrastructure and established commercializat

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the company's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a late-stage development biopharmaceutical company committed to th

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences: 2024 Truist Securities BioPharma Symposium on November 7, 2024 Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the company's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation. About Verastem Oncolo

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the company's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a late-stage development biopharmaceutical company committed to the devel

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024 at 3:35 pm EDT. A live webcast of the fireside chat can be accessed under events on the Verastem Oncology's website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a late-stage development biopharmaceutical company committed to the development and comm

Verastem Oncology (NASDAQ:VSTM) (the "Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET. To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative. Following the event, an archived replay of the fireside chat will be available on the investors section of the Company's website at www.verastem.com. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a development-stage biopharmaceutical company committed to

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the presentation and fireside chat will be available on the investors section of the Company's website at www.verastem.com. An archived replay of the presentation and fireside chat will be made available on the same websi

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET RBC Capital Markets Global Healthcare Conference; fireside chat on Wednesday, May 17, 2023 at 2:05 p.m. ET A live webcast of the presentation and fireside chat will be available on the investors section of the Company's website at www.verastem.com. An archived replay of the presentation and fireside chat will be made available on the same website for approximatel

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30 p.m. ET. A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com. An archived replay of the presentation will be made available on the same website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medic

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate virtually at the following upcoming investor conferences: H.C. Wainwright BIOCONNECT Virtual Conference; the fireside chat will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. ET B. Riley Oncology Conference; fireside chat on Friday, January 28, 2022 at 9:30 a.m. ET A webcast of the fireside chats will be available on the investors section of the Company's website at www.verastem.com. An archived presentation will be made available following each event. About Veraste

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening beginning Thursday, November 18, 2021 at 8:00 a.m. GMT (3:00 a.m. ET). A webcast of the presentation will be available on investors section of the Company's website at www.verastem.com. An archived presentation will be made available for 30 days. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercia

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 7:00 a.m. Eastern Time Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Time A webcast of the presentations will be available on the investors section of the Company's website at www.verastem.com. An archived presentation will be available for 90 days. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) (Verastem, Inc

Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com. An archived presentation will be available for 30 days. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed w

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST. The webcast of the fireside chat will be available on the “Media” section of the Company’s website at www.verastem.com under “Events & Presentations”. About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST. The webcast of the fireside chat will be available on the “Media” section of the Company’s website at www.verastem.com under “Events & Presentations”. About Verastem Oncology Verastem Oncology (Nasdaq:VSTM) is a development-stage biopharmaceutical company committed to the develop